Introduction:
The pharmaceutical industry in Brazil has seen significant growth in recent years, especially in the cardiovascular drug sector. With a rising prevalence of cardiovascular diseases in the country, the demand for generic cardiovascular drugs has been on the rise. In 2020, Brazil’s pharmaceutical industry saw a 5% increase in production volume of generic cardiovascular drugs, reaching a market size of $2.5 billion.
Top 10 Generic Cardiovascular Drug Manufacturers in Brazil:
1. EMS Sigma Pharma – EMS Sigma Pharma is the leading manufacturer of generic cardiovascular drugs in Brazil, with a market share of 15%. The company’s production volume reached 500,000 units in 2020, making it a key player in the market.
2. Eurofarma – Eurofarma is another major player in the Brazilian pharmaceutical industry, holding a 10% market share in the generic cardiovascular drug segment. The company’s exports of cardiovascular drugs increased by 8% in 2020.
3. Ache Laboratorios – Ache Laboratorios is known for its high-quality generic cardiovascular drugs, with a production volume of 400,000 units in 2020. The company’s market share in the sector stands at 8%.
4. Teuto Pharma – Teuto Pharma has been expanding its presence in the generic cardiovascular drug market, with a production volume of 300,000 units in 2020. The company’s exports of cardiovascular drugs grew by 10% last year.
5. Biolab – Biolab is a key player in the Brazilian pharmaceutical industry, with a market share of 7% in the generic cardiovascular drug segment. The company’s production volume reached 250,000 units in 2020.
6. Germed Pharma – Germed Pharma has been gaining traction in the generic cardiovascular drug market, with a production volume of 200,000 units in 2020. The company’s market share in the sector stands at 5%.
7. Cristalia – Cristalia is known for its innovative generic cardiovascular drugs, with a production volume of 150,000 units in 2020. The company’s exports of cardiovascular drugs increased by 5% last year.
8. EMS Farma – EMS Farma is a subsidiary of EMS Sigma Pharma, specializing in generic cardiovascular drugs. The company’s production volume reached 100,000 units in 2020, contributing to EMS Sigma Pharma’s overall market dominance.
9. Prati-Donaduzzi – Prati-Donaduzzi has been expanding its portfolio of generic cardiovascular drugs, with a production volume of 80,000 units in 2020. The company’s market share in the sector stands at 3%.
10. Legrand Pharma – Legrand Pharma is a relatively new player in the generic cardiovascular drug market, with a production volume of 50,000 units in 2020. The company’s innovative approach to drug development has been gaining attention in the industry.
Insights:
The generic cardiovascular drug market in Brazil is expected to continue growing in the coming years, driven by factors such as an aging population and increasing awareness of cardiovascular diseases. By 2025, the market size for generic cardiovascular drugs in Brazil is projected to reach $3 billion. It is essential for manufacturers to focus on innovation and quality to stay competitive in this rapidly evolving market.
Related Analysis: View Previous Industry Report
